Azaindole derivatives are inhibitors of microtubule dynamics, with anti-cancer and anti-angiogenic activities

British Journal of Pharmacology

Volumn 168, Issue 3, 2013, Pages 673-685

  Prudent, Renaud ^a,b   Vassal Stermann, Émilie ^b   Nguyen, Chi Hung ^c   Mollaret, Marjorie ^b   Viallet, Jean ^a   Desroches Castan, Agnès ^d   Martinez, Anne ^a   Barette, Caroline ^b   Pillet, Catherine ^b   Valdameri, Glaucio ^e   Soleilhac, Emmanuelle ^b   Di Pietro, Attilio ^e   Feige, Jean Jacques ^d   Billaud, Marc ^a   Florent, Jean Claude ^f   Lafanechère, Laurence ^a,b  

^a INSTITUT ALBERT BONNIOT   (France)

^b CEA GRENOBLE   (France)

^c INSTITUT CURIE   (France)

^d INSERM   (France)

^e UNIVERSITÉ LYON 1   (France)

^f CNRS   (France)

Author keywords

azaindole; cell based assay; high throughput screening; microtubule targeting agents

Indexed keywords

4 CHLORO 2 [1 (4 METHOXYPHENYL)ETHYL] 1 METHYL 1H PYRROLO[3,2 C]PYRIDINE; 4 CHLORO 2 [1 (4 METHOXYPHENYL)VINYL] 1 METHYL 1H PYRROLO[3,2 C]PYRIDINE; AZAINDOLE DERIVATIVE; CM 01; CM 02; COLCHICINE; INDOLE DERIVATIVE; PACLITAXEL; TUBULIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CHICKEN; CHORIOALLANTOIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSTASIS; DRUG CYTOTOXICITY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; EMBRYO; ENDOTHELIUM CELL; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROTUBULE ASSEMBLY; NONHUMAN; PRIORITY JOURNAL; SPHEROID CELL; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELLS, CULTURED; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENDOTHELIAL CELLS; HUMANS; INDOLES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUBULIN MODULATORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84872370315     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02230.x     Document Type: Article

References (37)

1. Akhmanova A, Hoogenraad CC, (2005). Microtubule plus-end-tracking proteins: mechanisms and functions. Curr Opin Cell Biol 17: 47-54.
2. Arora S, Wang XI, Keenan SM, Andaya C, Zhang Q, Peng Y, et al. (2009). Novel microtubule polymerization inhibitor with potent antiproliferative and antitumor activity. Cancer Res 69: 1910-1915.
3. Calligaris D, Verdier-Pinard P, Devred F, Villard C, Braguer D, Lafitte D, (2010). Microtubule targeting agents: from biophysics to proteomics. Cell Mol Life Sci 67: 1089-1104.
4. Coquelle FM, Vitre B, Arnal I, (2009). Structural basis of EB1 effects on microtubule dynamics. Biochem Soc Trans 37 (Pt 5): 997-1001.
5. De Rycker M, Rigoreau L, Dowding S, Parker PJ, (2009). A high-content, cell-based screen identifies micropolyin, a new inhibitor of microtubule dynamics. Chem Biol Drug Des 73: 599-610.
6. Dumontet C, Duran GE, Steger KA, Beketic-Oreskovic L, Sikic BI, (1996). Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res 56: 1091-1097.
7. Echalier A, Bettayeb K, Ferandin Y, Lozach O, Clement M, Valette A, et al. (2008). Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex. J Med Chem 51: 737-751.
8. Escuin D, Kline ER, Giannakakou P, (2005). Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Res 65: 9021-9028.
9. Fojo T, Menefee M, (2007). Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Ann Oncol 18 (Suppl. 5): v3-v8.
10. Gasparini G, (2001). Metronomic scheduling: the future of chemotherapy? Lancet Oncol 2: 733-740.
11. Harker WG, Sikic BI, (1985). Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA. Cancer Res 45: 4091-4096.
12. Holmfeldt P, Sellin ME, Gullberg M, (2009). Predominant regulators of tubulin monomer-polymer partitioning and their implication for cell polarization. Cell Mol Life Sci 66: 3263-3276.
13. Hong S, Kim J, Seo JH, Jung KH, Hong SS, (2012). Design, synthesis, and evaluation of 3,5-disubstituted 7-azaindoles as trk inhibitors with anticancer and antiangiogenic activities. J Med Chem 55: 5337-5349.
14. Honore S, Braguer D, (2011). Investigating microtubule dynamic instability using microtubule-targeting agents. Methods Mol Biol 777: 245-260.
15. Honore S, Pasquier E, Braguer D, (2005). Understanding microtubule dynamics for improved cancer therapy. Cell Mol Life Sci 62: 3039-3056.
16. Honore S, Pagano A, Gauthier G, Bourgarel-Rey V, Verdier-Pinard P, Civiletti K, et al. (2008). Antiangiogenic vinflunine affects EB1 localization and microtubule targeting to adhesion sites. Mol Cancer Ther 7: 2080-2089.
17. Jordan MA, Kamath K, (2007). How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets 7: 730-742.
18. Kasibhatla S, Baichwal V, Cai SX, Roth B, Skvortsova I, Skvortsov S, et al. (2007). MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps. Cancer Res 67: 5865-5871.
19. Kavallaris M, (2010). Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 10: 194-204.
20. Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, Haber M, et al. (1997). Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 100: 1282-1293.
21. Lafanechere L, (2008). Chemogenomics and cancer chemotherapy: cell-based assays to screen for small molecules that impair microtubule dynamics. Comb Chem High Throughput Screen 11: 617-623.
22. Lafanechere L, Job D, (2000). The third tubulin pool. Neurochem Res 25: 11-18.
23. Lafanechere L, Courtay-Cahen C, Kawakami T, Jacrot M, Rudiger M, Wehland J, et al. (1998). Suppression of tubulin tyrosine ligase during tumor growth. J Cell Sci 111 (Pt 2): 171-181.
24. Merchan JR, Jayaram DR, Supko JG, He X, Bubley GJ, Sukhatme VP, (2005). Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition. Int J Cancer 113: 490-498.
25. Nguyen CH, Bisagni E, Lhoste JM, (1986). Synthèse des dérivés N-5 substitués des 5H-pyrido [4,3-b] benzo [f] indoles, isomères des 6H-pyrido [4,3-b] carbazoles (ellipticines). Can J Chem 64: 454-551.
26. Nguyen TL, McGrath C, Hermone AR, Burnett JC, Zaharevitz DW, Day BW, et al. (2005). A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach. J Med Chem 48: 6107-6116.
27. Nien CY, Chen YC, Kuo CC, Hsieh HP, Chang CY, Wu JS, et al. (2010). 5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. J Med Chem 53: 2309-2313.
28. Pasquier E, Honore S, Pourroy B, Jordan MA, Lehmann M, Briand C, et al. (2005). Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res 65: 2433-2440.
29. Peris L, Thery M, Faure J, Saoudi Y, Lafanechere L, Chilton JK, et al. (2006). Tubulin tyrosination is a major factor affecting the recruitment of CAP-Gly proteins at microtubule plus ends. J Cell Biol 174: 839-849.
30. Pourroy B, Honore S, Pasquier E, Bourgarel-Rey V, Kruczynski A, Briand C, et al. (2006). Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cells. Cancer Res 66: 3256-3263.
31. Prise VE, Honess DJ, Stratford MR, Wilson J, Tozer GM, (2002). The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses. Int J Oncol 21: 717-726.
32. Small JV, Kaverina I, (2003). Microtubules meet substrate adhesions to arrange cell polarity. Curr Opin Cell Biol 15: 40-47.
33. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM, (2006). Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219-234.
34. Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, et al. (2001). Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 61: 6413-6422.
35. Tozer GM, Kanthou C, Baguley BC, (2005). Disrupting tumour blood vessels. Nat Rev Cancer 5: 423-435.
36. Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R, et al. (1999). Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93: 3064-3073.
37. Vassal E, Barette C, Fonrose X, Dupont R, Sans-Soleilhac E, Lafanechere L, (2006). Miniaturization and validation of a sensitive multiparametric cell-based assay for the concomitant detection of microtubule-destabilizing and microtubule-stabilizing agents. J Biomol Screen 11: 377-389.